Academic Publication

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

123

Citations

June 1, 2024

Published Date

Research Abstract & Technology Focus

No abstract provided for this literature.